Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

NCT02565758 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02565758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02565758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
September 18, 2015
Completion date
March 25, 2019
Enrollment
85 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, carcinoma of the breast, squamous cell carcinoma of the head and neck, undifferentiated pleomorphic sarcoma